# Innervace

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/innervace

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.innervace.com
- Total disclosed funding: $10M
- Latest round: Series A (Aug 8, 2022)
- Investors on record: 5

## About

Based in New York, US, and founded in 2020 by Douglas Smith, and D. Kacy Cullen Innervace, Inc., a University of Pennsylvania spinoff, is a company that develops and commercialize anatomical-based living implants for brain pathway reconstruction. In August 2022, Innervace, Inc. raised USD 9.99 million in series A funding led by new investor Deerfield Management, with participation from other new investors IP Group, Penn Medicine, WARF Ventures, and BioAdvance. As of 2022, Nader Halim is the Chief Executive Officer (CEO) of the company.

Innervace, Inc. is a regenerative therapy company that is developing technology that acts as pre-formed, anatomically inspired, implantable tissue pathways to replace lost connections in the brain caused by degeneration or injury. The company offers minimally invasive MRI (Magnetic resonance imaging) guided implantation with customizable length, dose, cell type, and cell source.

The company plans to use the August 2022 funding to support the cell therapy modality for neurological disorders treatment, including Parkinson’s Disease.

## Funding rounds

- Series A, Aug 8, 2022, $10M — Longview Innovation, BioAdvance, Deerfield Management, Penn Medicine, WARF Ventures

## Investors

- Longview Innovation (https://capitalatlas.ai/funds/longview-innovation) — Series A
- BioAdvance (https://capitalatlas.ai/funds/bioadvance) — Series A
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series A
- Penn Medicine — Series A
- WARF Ventures (https://capitalatlas.ai/funds/warf-ventures) — Series A